Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the grant of inducement equity awards outside of the Company's stockholder-approved equity compensation plans to Leonardo Nicacio in connection with his commencement of employment as Chief Medical Officer of the Company. The grants were approved by the Compensation Committee of the Board of Directors effective as of August 16, 2026, as inducements material to Mr. Nicacio entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- ATTENTION CAPR INVESTORS: Contact Berger Montague About a Capricor Therapeutics, Inc. Class Action LawsuitNational plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) ("Capricor" or the "Company") on behalf of investors who purchased or acquired Capricor securities during the period from December 17, 2025 through July 26, 2026 (the "Class Period").Investor Deadline: Investors who purchased or acquired Capricor securities during the Class Period may, no later than...
- Nasus Pharma Reports First Half 2026 Financial Results and Provides Business UpdateAppointed Pharma Industry Veteran Brendan O’Grady as Chief Executive Officer
- MeijerMeijer Makes Immunizations More Convenient with New Scheduling Feature and Expanded Mobile Vaccine OfferingsMidwest retailer announces more options to meet customer vaccination needs heading into new school year and cold and flu season — Meijer is helping more customers take charge of their health by making recommended vaccinations easier to...
- First Ascent BiomedicalFirst Ascent Biomedical Names Dr. Gilberto Lopes Chairman of Its Medical Advisory BoardUniversity of Miami medical oncology chief and Sylvester global oncology leader will guide scientific strategy, clinical evidence and the responsible advancement of Functional Precision Oncology — First Ascent Biomedical, a precision oncology...
- Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for IbezapolstatThe proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the...
- OncoC4OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous formulation designed to provide gradual systemic exposure, potentially mitigating CRS risk — ROCKVILLE, Md., Aug. 17, 2026 -- OncoC4 Inc., a...
- Sinovac Biotech Ltd.SINOVAC Reports Unaudited First Half of 2026 Financial ResultsBEIJING, August 17, 2026--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it filed its unaudited financial results for the six months ended June 30, 2026 with the U.S. Securities and Exchange Commission.
- Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine programEvaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, expands it pipeline of cancer vaccine programs with EVX-05 against the deadly brain cancer glioblastoma.
- OS TherapiesOS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory UpdatesUp to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million funded at the August 10, 2026 first closingFDA Type C Statistical Methods Meeting mid-September 2026 meeting to review 2.5-year Overall Survival data and confirmatory Phase 3 trial design to gain alignment on statistical analysis plan for BLA submission under the Accelerated Approval ProgramInterim 3-year Overall Survival data expected in early September 2026 ahead of...
- Computer System Validation (CSV) Implementation Boot Camp: Practical Validation of GxP Computerised Systems (Aug 19th - Aug 21st, 2026)As life sciences, pharmaceutical, biotech, and medical device organizations accelerate digital transformation highlighted by the shift toward FDA Computer Software Assurance (CSA) draft guidance, GAMP® 5 (Second Edition) risk-based validation, and cloud/SaaS deployments ensuring 21 CFR Part 11 and EU Annex 11 regulatory compliance remains paramount. This practical training course equips QA/QC professionals, IT system owners, and regulatory auditors with actionable methodologies for modernizing the System Development Life Cycle (SDLC), conducting critical-thinking risk assessments, writing IQ/OQ/PQ test protocols, maintaining data integrity, and establishing audit-ready documentation across the full system lifecycle.
- FDA Inspection Readiness in the AI Era 2026 (Aug 20th - Aug 21st, 2026)Opportunities include AI-enabled continuous inspection readiness, stronger GMP and data-integrity compliance, more effective CAPA and quality-culture systems, and training to help pharma and biotech firms meet evolving FDA expectations.